SESNライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (8 3月 2023 @ 06:00):

Stats
本日の出来高	1.78M
平均出来高	1.24M
時価総額	127.96M
EPS	$-53.13 ( 2023-09-29 )
Last Dividend	$0.360 ( 2023-03-06 )
Next Dividend	$0 ( N/A )
P/E	-6.29
ATR14	$0.0360 (5.73%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-06	Kelly Steven	Buy	600 000	Stock Option (Right to Buy)
2023-06-06	Zweifach Sanford S	Buy	38 700	Stock Option (Right to Buy)
2023-06-06	Morris Richard Steven	Buy	238 000	Stock Option (Right to Buy)
2023-06-06	Torok Michael	Buy	38 700	Stock Option (Right to Buy)
2023-06-06	Klichinsky Michael	Buy	238 000	Stock Option (Right to Buy)

INSIDER POWER
76.64
Last 87 transactions
Buy: 18 644 112 \| Sell: 1 508 721

ボリューム相関

長: 0.00 (neutral)

短: -0.48 (neutral)

Signal:(57.604) Neutral

Sesen Bio Inc 相関

10 最も正の相関
BOCH	0.945
SHSP	0.905
DYNT	0.846
SGC	0.836
MMAC	0.83
WWD	0.829
SYKE	0.826
LIVE	0.825
DGLY	0.823
ECOR	0.817

10 最も負の相関
GAINL	-0.898
APOP	-0.887
TDAC	-0.884
RMRM	-0.88
ISNS	-0.872
SVOK	-0.829
VERA	-0.822
AHPI	-0.801

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Sesen Bio Inc 相関 - 通貨/商品

-0.56
( weak negative )

-0.49
( neutral )

0.00
( neutral )

-0.45
( neutral )

-0.31
( neutral )

0.47
( neutral )

Sesen Bio Inc 財務諸表

Annual	2022
収益:	$40.00M
総利益:	$40.00M (100.00 %)
EPS:	$-1.990

FY	2022
収益:	$40.00M
総利益:	$40.00M (100.00 %)
EPS:	$-1.990

FY	2021
収益:	$26.54M
総利益:	$0.00 (0.00 %)
EPS:	$-0.00184

FY	2020
収益:	$11.24M
総利益:	$11.24 (0.00 %)
EPS:	$-0.190

Financial Reports:

No articles found.

Sesen Bio Inc Dividends

(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.360 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Sesen Bio Inc Dividend Information - Dividend Knight

Dividend Sustainability Score: 5.13 - average (38.17%) | Divividend Growth Potential Score: 0.276 - No dividend growth expected in the near future

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.360	2023-03-06
Last Dividend	$0.360	2023-03-06
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.360	--
Avg. Dividend % Per Year	18.77%	--
Score	4.82	--
Div. Sustainability Score	5.13
Div.Growth Potential Score	0.276
Div. Directional Score	2.70	--

Next Divdend (Est)
(2024-04-29)

$0.720 Estimate 2.50 %

Dividend Stability

0.20 Very Poor

Dividend Score

4.82

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2023	$0.360	56.30%
2024	$0	0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-1.605	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.761	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-0.910	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	7.53	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	7.27	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	6.42	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0257	-1.500	9.57	-10.00	[0 - 0.6]
interestCoverageTTM	11.34	1.000	6.91	6.91	[3 - 30]
operatingCashFlowPerShareTTM	0.0199	2.00	9.99	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.0166	2.00	9.99	10.00	[0 - 20]
debtEquityRatioTTM	0.0593	-1.500	9.76	-10.00	[0 - 2.5]
grossProfitMarginTTM	1.000	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-1.510	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.292	1.000	9.49	9.49	[0.2 - 2]
assetTurnoverTTM	0.474	0.800	-0.172	-0.138	[0.5 - 2]
Total Score				5.13

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.312	1.000	-0.133	0	[1 - 100]
returnOnEquityTTM	-0.910	2.50	-7.21	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.0166	2.00	9.99	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.0199	2.00	9.99	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0158	1.000	-2.10	0	[0.1 - 0.5]
Total Score				0.276

Sesen Bio Inc

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.